{"title":"Growth Hormone Peptides","description":"\u003cp\u003eResearch-grade growth hormone secretagogue peptides including GHRP, CJC, Ipamorelin, and Tesamorelin. High-purity, lab-tested. For research use only.\u003c\/p\u003e","products":[{"product_id":"tesamorelin-5mg","title":"Tesamorelin 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/Tesa_5mg_gloss.png?v=1779035727\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eTesamorelin 5mg is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed for research and laboratory use. Tesamorelin is a stabilised 44-amino acid GHRH peptide with a trans-3-hexenoic acid modification at the N-terminus, conferring enhanced stability relative to endogenous GHRH(1–44). It has been investigated in preclinical and clinical research settings for its effects on GH and IGF-1 axis stimulation, visceral adiposity, and metabolic regulation. Each vial is manufactured to pharmaceutical-grade purity standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions studying GHRH receptor pharmacology, GH axis modulation, and metabolic biology. Store in a cool, dry place away from direct light. For research purposes only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003cp\u003eSpecifications: Active Ingredient: Tesamorelin (synthetic GHRH analogue) Concentration: 5mg per vial Molecular Formula: C₂₂₁H₃₆₆N₆₀O₆₇S Molecular Weight: 5,202.8 g\/mol Structure: 44-amino acid GHRH analogue with N-terminal trans-3-hexenoic acid modification CAS Number: 86168-78-7 Purity: ≥98% (HPLC) Form: Lyophilised powder Appearance: White to off-white lyophilised powder pH (reconstituted): 4.0–5.5 Endotoxin Level: \u0026lt;5 EU\/vial Storage: 2–8°C (refrigerated) Shelf Life: 24 months from manufacture date Reconstitution: Sterile water for injection Intended Use: Laboratory and research applications only\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store in original sealed vial at 2–8°C, protected from direct light and moisture. Stable for 24 months from manufacture date. Do not freeze. Minimise temperature fluctuations. Storage After Reconstitution: Store reconstituted solution at 2–8°C, protected from light. Use aseptic technique throughout. Avoid repeated freeze-thaw cycles; if freezing is necessary, use single-use aliquots at −20°C for up to 3 months. For research use only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eTesamorelin: Design and GHRH Receptor Pharmacology\u003c\/strong\u003e\u003cbr\u003eFalutz J, et al. (2007). \u003cem\u003eMetabolic effects of a growth hormone–releasing factor in patients with HIV.\u003c\/em\u003e New England Journal of Medicine, 357(23), 2359–2370. \u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa072375\"\u003ehttps:\/\/doi.org\/10.1056\/NEJMoa072375\u003c\/a\u003e\u003cbr\u003ePivotal Phase 3 clinical research study demonstrating tesamorelin’s ability to significantly reduce visceral adipose tissue and elevate IGF-1 levels via sustained GHRH receptor activation, establishing its pharmacodynamic profile and providing the key translational reference for tesamorelin GH-axis research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTesamorelin and GH\/IGF-1 Axis Stimulation\u003c\/strong\u003e\u003cbr\u003eFalutz J, et al. (2010). \u003cem\u003eEffects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.\u003c\/em\u003e Journal of Acquired Immune Deficiency Syndromes, 53(3), 311–322. \u003ca href=\"https:\/\/doi.org\/10.1097\/QAI.0b013e3181cbdaff\"\u003ehttps:\/\/doi.org\/10.1097\/QAI.0b013e3181cbdaff\u003c\/a\u003e\u003cbr\u003eRandomised, placebo-controlled trial with safety extension evaluating tesamorelin’s sustained effects on GH and IGF-1 secretion and visceral fat reduction, providing long-term pharmacodynamic and tolerability data relevant to GHRH analogue research protocols.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRH Receptor Structure and Agonist Binding\u003c\/strong\u003e\u003cbr\u003eMayo KE, et al. (1992). \u003cem\u003eMolecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone.\u003c\/em\u003e Molecular Endocrinology, 6(10), 1734–1744. \u003ca href=\"https:\/\/doi.org\/10.1210\/mend.6.10.1333056\"\u003ehttps:\/\/doi.org\/10.1210\/mend.6.10.1333056\u003c\/a\u003e\u003cbr\u003eReports the cloning and characterisation of the GHRH receptor (GHRHR), establishing the molecular target through which tesamorelin exerts its GH-releasing effects and providing the structural and signalling context for GHRH receptor agonist research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTesamorelin and Visceral Adiposity: Metabolic Research Context\u003c\/strong\u003e\u003cbr\u003eStanley TL, et al. (2012). \u003cem\u003eEffect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.\u003c\/em\u003e JAMA, 312(4), 380–389. \u003ca href=\"https:\/\/doi.org\/10.1001\/jama.2014.8334\"\u003ehttps:\/\/doi.org\/10.1001\/jama.2014.8334\u003c\/a\u003e\u003cbr\u003eRandomised clinical trial demonstrating tesamorelin’s significant reduction of visceral and hepatic fat via GH\/IGF-1 axis activation, providing quantitative metabolic and body composition data relevant to researchers studying GHRH analogue effects on lipid metabolism and adipose tissue biology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTesamorelin and Cognitive Function Research\u003c\/strong\u003e\u003cbr\u003eBaker LD, et al. (2012). \u003cem\u003eEffects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults.\u003c\/em\u003e Archives of Neurology, 69(11), 1420–1429. \u003ca href=\"https:\/\/doi.org\/10.1001\/archneurol.2012.1970\"\u003ehttps:\/\/doi.org\/10.1001\/archneurol.2012.1970\u003c\/a\u003e\u003cbr\u003eRandomised controlled trial investigating tesamorelin’s effects on cognitive function in older adults and those with mild cognitive impairment, demonstrating improvements in executive function and verbal memory — expanding the research scope of GHRH analogue studies into neuroendocrine and cognitive biology.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248637894999,"sku":"TSM5","price":23.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/Tesa_5mg_gloss.png?v=1779035728"},{"product_id":"ipamorelin-5mg","title":"Ipamorelin 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/Ipamorelin5mgG.png?v=1779542231\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eIpamorelin 5mg is a synthetic pentapeptide growth hormone secretagogue (GHS) designed for research and laboratory use. Ipamorelin acts as a selective agonist of the ghrelin receptor (GHS-R1a), stimulating pulsatile growth hormone release from anterior pituitary somatotrophs with high selectivity and minimal effect on cortisol, prolactin, or ACTH — distinguishing it from earlier GHRPs such as GHRP-6. It has been investigated in preclinical models for its effects on GH axis regulation, body composition, bone density, gut motility, and age-related GH decline. It is frequently studied in combination with GHRH analogues such as CJC-1295 to produce synergistic GH pulse amplification. Each vial is manufactured to pharmaceutical-grade purity standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions studying GHS-R1a pharmacology, GH secretion dynamics, and metabolic regulation. Store at 2–8°C. For research purposes only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003cp\u003eSpecifications: Active Ingredient: Ipamorelin Concentration: 5mg per vial Peptide Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ Molecular Formula: C₃₈H₄₉N₉O₅ Molecular Weight: 711.85 g\/mol Classification: Selective GHS-R1a agonist (ghrelin receptor agonist) Selectivity: Highly selective for GH secretion; minimal ACTH, cortisol, or prolactin stimulation Purity: ≥98% (HPLC) Form: Lyophilised powder Endotoxin Level: \u0026lt;5 EU\/vial Storage: 2–8°C (refrigerated) Shelf Life: 24 months from manufacture date Reconstitution: Bacteriostatic water Intended Use: Laboratory and research applications only\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store in original sealed vial at 2–8°C, away from light and moisture. Stable for 24 months from manufacture date. Storage After Reconstitution: Store reconstituted solution at 2–8°C and use within 21 days. Do not freeze reconstituted solution. Minimise light exposure. For research use only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin: Discovery as the First Selective GH Secretagogue\u003c\/strong\u003e\u003cbr\u003eRaun K, et al. (1998). \u003cem\u003eIpamorelin, the first selective growth hormone secretagogue.\u003c\/em\u003e European Journal of Endocrinology, 139(5), 552–561. \u003ca href=\"https:\/\/doi.org\/10.1530\/eje.0.1390552\"\u003ehttps:\/\/doi.org\/10.1530\/eje.0.1390552\u003c\/a\u003e\u003cbr\u003eThe foundational characterisation study establishing ipamorelin as the first highly selective GH secretagogue, demonstrating potent GH release with minimal effect on ACTH, cortisol, and prolactin in rat models — distinguishing it from GHRP-6 and GHRP-2 and establishing its selectivity profile for GH-axis research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin and GHS-R1a Receptor Pharmacology\u003c\/strong\u003e\u003cbr\u003eHoward AD, et al. (1996). \u003cem\u003eA receptor in pituitary and hypothalamus that functions in growth hormone release.\u003c\/em\u003e Science, 273(5277), 974–977. \u003ca href=\"https:\/\/doi.org\/10.1126\/science.273.5277.974\"\u003ehttps:\/\/doi.org\/10.1126\/science.273.5277.974\u003c\/a\u003e\u003cbr\u003eReports the cloning and characterisation of GHS-R1a — the primary molecular target of ipamorelin — establishing the receptor biology and signal transduction pathways through which ipamorelin stimulates pulsatile GH secretion from anterior pituitary somatotrophs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin and Postoperative Gut Motility\u003c\/strong\u003e\u003cbr\u003ePoitras P, et al. (2005). \u003cem\u003eIpamorelin, a ghrelin mimetic, stimulates gastrointestinal motility in postoperative ileus in rats.\u003c\/em\u003e Neurogastroenterology \u0026amp; Motility, 17(6), 892–901. \u003ca href=\"https:\/\/doi.org\/10.1111\/j.1365-2982.2005.00699.x\"\u003ehttps:\/\/doi.org\/10.1111\/j.1365-2982.2005.00699.x\u003c\/a\u003e\u003cbr\u003eDemonstrates ipamorelin’s ability to stimulate gastrointestinal motility and accelerate recovery from postoperative ileus in rat models via GHS-R1a activation in the enteric nervous system, expanding its research scope beyond the GH axis into gastrointestinal biology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin and Bone Density in Preclinical Models\u003c\/strong\u003e\u003cbr\u003eSvensson J, et al. (2000). \u003cem\u003eTwo-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.\u003c\/em\u003e (See also: Johansen PB, et al. (1999). \u003cem\u003eIpamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.\u003c\/em\u003e Growth Hormone \u0026amp; IGF Research, 9(2), 106–113.) \u003ca href=\"https:\/\/doi.org\/10.1054\/ghir.1999.9998\"\u003ehttps:\/\/doi.org\/10.1054\/ghir.1999.9998\u003c\/a\u003e\u003cbr\u003eDemonstrates ipamorelin-induced longitudinal bone growth and increased bone mineral density in rat models via GH\/IGF-1 axis stimulation, providing key preclinical data for researchers investigating GHS-R1a agonism in skeletal biology and bone metabolism.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin + CJC-1295 Synergy: Combined GH Secretagogue Research\u003c\/strong\u003e\u003cbr\u003eTeichman SL, et al. (2006). \u003cem\u003eProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.\u003c\/em\u003e Journal of Clinical Endocrinology \u0026amp; Metabolism, 91(3), 799–805. \u003ca href=\"https:\/\/doi.org\/10.1210\/jc.2005-1536\"\u003ehttps:\/\/doi.org\/10.1210\/jc.2005-1536\u003c\/a\u003e\u003cbr\u003eProvides the pharmacodynamic basis for combining GHRH analogues with GHS-R1a agonists such as ipamorelin, demonstrating synergistic amplification of GH pulse amplitude — the key reference for researchers designing combination CJC-1295 + ipamorelin protocols.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248643137879,"sku":"IP5","price":17.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/Ipamorelin5mgG.png?v=1779542231"},{"product_id":"ipamorelin-10mg","title":"Ipamorelin 10mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/Ipamorelin10mgG.png?v=1779543400\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eIpamorelin is a selective growth hormone secretagogue designed to stimulate natural GH release. This 10mg formulation supports lean muscle development, recovery optimization, and metabolic efficiency. Ideal for those seeking targeted performance enhancement with a research-backed peptide. Each vial delivers pharmaceutical-grade purity for consistent results.\u003c\/p\u003e\n\u003cp\u003ePeptide Type: Growth Hormone Secretagogue Active Ingredient: Ipamorelin Concentration: 10mg per vial Purity: Pharmaceutical-grade Mechanism: Selective GH stimulation Primary Benefits: Lean muscle support, recovery enhancement, metabolic optimization Recommended Use: Performance and body composition optimization Storage: Cool, dry conditions Shelf Life: 24 months from manufacture\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C38H49N9O5 Molecular Weight: 711.85 g\/mol Structure: Pentapeptide (5 amino acid chain) Amino Acid Sequence: Alanyl-D-2-methylalanyl-D-2-methyltryptophyl-lysyl-prolyl amide CAS Number: 170851-70-4 Classification: Synthetic growth hormone-releasing peptide (GHRP) analog Stability: Stable under standard storage conditions\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin: Discovery as the First Selective GH Secretagogue\u003c\/strong\u003e\u003cbr\u003eRaun K, et al. (1998). \u003cem\u003eIpamorelin, the first selective growth hormone secretagogue.\u003c\/em\u003e European Journal of Endocrinology, 139(5), 552–561. \u003ca href=\"https:\/\/doi.org\/10.1530\/eje.0.1390552\"\u003ehttps:\/\/doi.org\/10.1530\/eje.0.1390552\u003c\/a\u003e\u003cbr\u003eThe foundational characterisation study establishing ipamorelin as the first highly selective GH secretagogue, demonstrating potent GH release with minimal effect on ACTH, cortisol, and prolactin in rat models — distinguishing it from GHRP-6 and GHRP-2 and establishing its selectivity profile for GH-axis research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin and GHS-R1a Receptor Pharmacology\u003c\/strong\u003e\u003cbr\u003eHoward AD, et al. (1996). \u003cem\u003eA receptor in pituitary and hypothalamus that functions in growth hormone release.\u003c\/em\u003e Science, 273(5277), 974–977. \u003ca href=\"https:\/\/doi.org\/10.1126\/science.273.5277.974\"\u003ehttps:\/\/doi.org\/10.1126\/science.273.5277.974\u003c\/a\u003e\u003cbr\u003eReports the cloning and characterisation of GHS-R1a — the primary molecular target of ipamorelin — establishing the receptor biology and signal transduction pathways through which ipamorelin stimulates pulsatile GH secretion from anterior pituitary somatotrophs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin and Postoperative Gut Motility\u003c\/strong\u003e\u003cbr\u003ePoitras P, et al. (2005). \u003cem\u003eIpamorelin, a ghrelin mimetic, stimulates gastrointestinal motility in postoperative ileus in rats.\u003c\/em\u003e Neurogastroenterology \u0026amp; Motility, 17(6), 892–901. \u003ca href=\"https:\/\/doi.org\/10.1111\/j.1365-2982.2005.00699.x\"\u003ehttps:\/\/doi.org\/10.1111\/j.1365-2982.2005.00699.x\u003c\/a\u003e\u003cbr\u003eDemonstrates ipamorelin’s ability to stimulate gastrointestinal motility and accelerate recovery from postoperative ileus in rat models via GHS-R1a activation in the enteric nervous system, expanding its research scope beyond the GH axis into gastrointestinal biology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin and Bone Density in Preclinical Models\u003c\/strong\u003e\u003cbr\u003eSvensson J, et al. (2000). \u003cem\u003eTwo-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.\u003c\/em\u003e (See also: Johansen PB, et al. (1999). \u003cem\u003eIpamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.\u003c\/em\u003e Growth Hormone \u0026amp; IGF Research, 9(2), 106–113.) \u003ca href=\"https:\/\/doi.org\/10.1054\/ghir.1999.9998\"\u003ehttps:\/\/doi.org\/10.1054\/ghir.1999.9998\u003c\/a\u003e\u003cbr\u003eDemonstrates ipamorelin-induced longitudinal bone growth and increased bone mineral density in rat models via GH\/IGF-1 axis stimulation, providing key preclinical data for researchers investigating GHS-R1a agonism in skeletal biology and bone metabolism.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin + CJC-1295 Synergy: Combined GH Secretagogue Research\u003c\/strong\u003e\u003cbr\u003eTeichman SL, et al. (2006). \u003cem\u003eProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.\u003c\/em\u003e Journal of Clinical Endocrinology \u0026amp; Metabolism, 91(3), 799–805. \u003ca href=\"https:\/\/doi.org\/10.1210\/jc.2005-1536\"\u003ehttps:\/\/doi.org\/10.1210\/jc.2005-1536\u003c\/a\u003e\u003cbr\u003eProvides the pharmacodynamic basis for combining GHRH analogues with GHS-R1a agonists such as ipamorelin, demonstrating synergistic amplification of GH pulse amplitude — the key reference for researchers designing combination CJC-1295 + ipamorelin protocols.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution (Lyophilized Powder): Temperature: 2–8°C (refrigerated) or 15–25°C (room temperature) Environment: Dark, dry location away from direct sunlight Humidity: Below 60% relative humidity Container: Original sealed vial with desiccant Shelf Life: 24 months from manufacture date Handling: Minimize exposure to air and moisture Storage After Reconstitution (Liquid Solution): Temperature: 2–8°C (refrigerated) Duration: Use within 14–30 days depending on reconstitution medium Container: Sterile vial with bacteriostatic water or saline Stability: Reduced once reconstituted; degradation accelerates at room temperature Handling: Store upright, avoid repeated freeze-thaw cycles Discard: Any solution showing discoloration, cloudiness, or particulates\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248644251991,"sku":"IP10","price":29.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/Ipamorelin10mgG.png?v=1779543400"},{"product_id":"ghrp-2-5mg","title":"GHRP-2 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/ghrp-2-5mg_d6af29de-fe73-44fe-bf4a-365a186d3f9b.png?v=1779536598\" alt=\"\"\u003eGHRP-2 5mg is a synthetic hexapeptide compound designed for research and laboratory use. This high-purity formulation delivers 5 milligrams of Growth Hormone Releasing Peptide-2, a potent growth hormone secretagogue that acts on the ghrelin receptor to stimulate endogenous growth hormone release, suitable for scientific investigation and experimental applications. Each vial is manufactured to exacting standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions exploring growth hormone axis regulation, metabolic function, and recovery pathway studies. Store in a cool, dry place away from direct light. For research purposes only.\u003c\/p\u003e\n\u003cp\u003eSpecifications: Active Ingredient: GHRP-2 (Growth Hormone Releasing Peptide-2) Concentration: 5mg per vial Purity: Research-grade Format: Lyophilized powder Storage: Cool, dry environment, 2–8°C (refrigerated) Shelf Life: Refer to batch documentation for expiration details Intended Use: Laboratory and research applications only Quality Standard: Manufactured to pharmaceutical-grade consistency protocols Suitable for qualified researchers, academic institutions, and licensed laboratories conducting growth hormone and metabolic peptide research.\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C₄₅H₅₅N₉O₆ Molecular Weight: 817.98 g\/mol CAS Number: 158861-67-7 Sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ Sequence Classification: Synthetic hexapeptide; growth hormone secretagogue and ghrelin receptor agonist Mechanism: Stimulates pulsatile growth hormone release from the anterior pituitary via ghrelin receptor (GHSR-1a) activation, independent of GHRH pathways, without significantly affecting cortisol or prolactin levels Purity Analysis: ≥98% by HPLC This molecular data supports advanced research into growth hormone secretion mechanisms, IGF-1 axis modulation, and metabolic regulation studies.\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store the sealed vial at 2–8°C (refrigerated) or at room temperature (15–25°C) in a cool, dry place away from direct sunlight and heat sources. Keep in original packaging to protect from light exposure. Unopened vials maintain stability for the duration specified in batch documentation when stored under these conditions. Storage After Reconstitution: Once reconstituted with bacteriostatic water or sterile saline, store the solution at 2–8°C (refrigerated). Reconstituted solution should be used within the timeframe indicated in your batch documentation. Avoid repeated freeze-thaw cycles, which may compromise peptide integrity. Keep the vial upright and away from direct light during storage. General Handling: Maintain sterile technique during reconstitution. Do not expose to extreme temperatures or prolonged room temperature conditions after mixing. For research use only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRP-2: Potency and GH Secretagogue Profile\u003c\/strong\u003e\u003cbr\u003eBowers CY. (1998). \u003cem\u003eGrowth hormone-releasing peptide (GHRP).\u003c\/em\u003e Cellular and Molecular Life Sciences, 54(12), 1316–1329. \u003ca href=\"https:\/\/doi.org\/10.1007\/s000180050257\"\u003ehttps:\/\/doi.org\/10.1007\/s000180050257\u003c\/a\u003e\u003cbr\u003eComprehensive review by the pioneer of GHRP research, characterising GHRP-2 as one of the most potent synthetic GH secretagogues, detailing its hexapeptide structure, GHS-R1a binding affinity, and comparative GH-releasing potency relative to GHRP-6 and other GHRPs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRP-2 Dose–Response and GH\/IGF-1 Axis Stimulation\u003c\/strong\u003e\u003cbr\u003eArvat E, et al. (1997). \u003cem\u003eGHRP-2, a synthetic hexapeptide, stimulates GH secretion in normal subjects and in patients with GH deficiency.\u003c\/em\u003e Journal of Endocrinological Investigation, 20(3), 140–146. \u003ca href=\"https:\/\/doi.org\/10.1007\/BF03347955\"\u003ehttps:\/\/doi.org\/10.1007\/BF03347955\u003c\/a\u003e\u003cbr\u003eDemonstrates dose-dependent GH stimulation by GHRP-2 in both healthy subjects and GH-deficient patients, with minimal effect on cortisol and prolactin, establishing its selectivity profile and providing key pharmacodynamic data for GH-axis research models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRP-2 vs. GHRP-6: Comparative Selectivity and Cortisol Effects\u003c\/strong\u003e\u003cbr\u003eGhigo E, et al. (1994). \u003cem\u003eGrowth hormone-releasing peptides.\u003c\/em\u003e European Journal of Endocrinology, 131(5), 445–460. \u003ca href=\"https:\/\/doi.org\/10.1530\/eje.0.1310445\"\u003ehttps:\/\/doi.org\/10.1530\/eje.0.1310445\u003c\/a\u003e\u003cbr\u003eComparative review of GHRP-2 and GHRP-6 pharmacology, demonstrating that GHRP-2 produces greater GH release with a more favourable cortisol and prolactin profile than GHRP-6, providing essential context for researchers selecting between GHS-R1a agonists for GH-axis studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHS-R1a Receptor and GHRP-2 Binding Mechanism\u003c\/strong\u003e\u003cbr\u003eHoward AD, et al. (1996). \u003cem\u003eA receptor in pituitary and hypothalamus that functions in growth hormone release.\u003c\/em\u003e Science, 273(5277), 974–977. \u003ca href=\"https:\/\/doi.org\/10.1126\/science.273.5277.974\"\u003ehttps:\/\/doi.org\/10.1126\/science.273.5277.974\u003c\/a\u003e\u003cbr\u003eReports the cloning and characterisation of GHS-R1a — the primary molecular target of GHRP-2 — establishing the receptor biology and signal transduction pathways through which GHRP-2 stimulates somatotroph GH secretion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRP-2 and Cardioprotection: GH-Independent Effects\u003c\/strong\u003e\u003cbr\u003eBerlanga-Acosta J, et al. (2017). \u003cem\u003eSynthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects.\u003c\/em\u003e Clinical Medicine Insights: Cardiology, 11, 1179546817694558. \u003ca href=\"https:\/\/doi.org\/10.1177\/1179546817694558\"\u003ehttps:\/\/doi.org\/10.1177\/1179546817694558\u003c\/a\u003e\u003cbr\u003eReviews the GH-independent cytoprotective and cardioprotective effects of GHRP-2 and related secretagogues, covering anti-apoptotic, anti-inflammatory, and anti-fibrotic mechanisms observed in cardiac, hepatic, and renal tissue models — expanding the research scope beyond the GH axis.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248666141015,"sku":"G25","price":13.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/ghrp-2-5mg_d6af29de-fe73-44fe-bf4a-365a186d3f9b.png?v=1779536598"},{"product_id":"ghrp-6-5mg","title":"GHRP-6 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/GHRP-65mg.png?v=1779536247\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eGHRP-6 is a growth hormone releasing peptide designed for research and experimental use. This 5mg formulation supports investigation into growth hormone secretion pathways and metabolic processes. Ideal for qualified researchers and laboratories exploring peptide mechanisms in controlled settings. Each vial contains precisely measured GHRP-6 for consistent experimental protocols.\u003c\/p\u003e\n\u003cp\u003eSpecification Peptide: GHRP-6 (Growth Hormone Releasing Peptide-6) Quantity: 5mg per vial Purity: Research grade Form: Lyophilized powder Intended Use: Laboratory and research applications only Storage: Keep in cool, dry conditions away from direct light Reconstitution: Compatible with sterile bacteriostatic water or saline solution\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C40H69N15O10 Molecular Weight: 873.07 g\/mol Structure: Hexapeptide Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 CAS Number: 87616-84-0 Classification: Research peptide, growth hormone secretagogue\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution Store lyophilized GHRP-6 vials at 2–8°C (refrigerated) or at room temperature (15–25°C) in a cool, dry place away from direct sunlight and moisture. Properly sealed vials maintain stability for extended periods under these conditions. Keep away from heat sources and humidity. Storage After Reconstitution Once reconstituted with sterile bacteriostatic water or saline solution, store the solution at 2–8°C (refrigerated). Reconstituted peptide solutions typically remain stable for 2–4 weeks when stored properly in sterile conditions. Always use sterile technique during reconstitution and storage to prevent contamination. Do not freeze reconstituted solutions unless specifically required for your research protocol.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRP-6: Discovery and GH-Releasing Activity\u003c\/strong\u003e\u003cbr\u003eBowers CY, et al. (1991). \u003cem\u003eOn the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.\u003c\/em\u003e Endocrinology, 128(4), 2027–2035. \u003ca href=\"https:\/\/doi.org\/10.1210\/endo-128-4-2027\"\u003ehttps:\/\/doi.org\/10.1210\/endo-128-4-2027\u003c\/a\u003e\u003cbr\u003eFoundational study characterising GHRP-6 as a potent synthetic hexapeptide GH secretagogue, demonstrating dose-dependent GH release from pituitary somatotrophs both in vitro and in vivo, and establishing its pharmacological profile as distinct from GHRH.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRP-6 and the Ghrelin Receptor (GHS-R1a)\u003c\/strong\u003e\u003cbr\u003eHoward AD, et al. (1996). \u003cem\u003eA receptor in pituitary and hypothalamus that functions in growth hormone release.\u003c\/em\u003e Science, 273(5277), 974–977. \u003ca href=\"https:\/\/doi.org\/10.1126\/science.273.5277.974\"\u003ehttps:\/\/doi.org\/10.1126\/science.273.5277.974\u003c\/a\u003e\u003cbr\u003eReports the cloning and characterisation of the growth hormone secretagogue receptor (GHS-R1a) — the primary molecular target of GHRP-6 — establishing the receptor biology underpinning all GHRP research and its relationship to the endogenous ghrelin system.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRP-6 Synergy with GHRH in GH Secretion\u003c\/strong\u003e\u003cbr\u003ePandya N, et al. (1998). \u003cem\u003eGrowth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation.\u003c\/em\u003e Journal of Clinical Endocrinology \u0026amp; Metabolism, 83(4), 1186–1189. \u003ca href=\"https:\/\/doi.org\/10.1210\/jcem.83.4.4716\"\u003ehttps:\/\/doi.org\/10.1210\/jcem.83.4.4716\u003c\/a\u003e\u003cbr\u003eDemonstrates that GHRP-6’s maximal GH-releasing effect requires intact endogenous GHRH signalling, establishing the synergistic relationship between GHS-R1a agonism and GHRH receptor activation — key context for combination peptide research protocols.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRP-6 and Ghrelin: Appetite and Metabolic Regulation\u003c\/strong\u003e\u003cbr\u003eKojima M, et al. (1999). \u003cem\u003eGhrelin is a growth-hormone-releasing acylated peptide from stomach.\u003c\/em\u003e Nature, 402(6762), 656–660. \u003ca href=\"https:\/\/doi.org\/10.1038\/45230\"\u003ehttps:\/\/doi.org\/10.1038\/45230\u003c\/a\u003e\u003cbr\u003eThe landmark paper identifying ghrelin as the endogenous ligand for GHS-R1a — the same receptor activated by GHRP-6 — establishing the mechanistic link between GHRP-6 activity, appetite stimulation, and metabolic regulation that underpins its orexigenic effects in research models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRP-6 Cardioprotective Effects in Ischaemia Models\u003c\/strong\u003e\u003cbr\u003eGranado M, et al. (2006). \u003cem\u003eGhrelin and growth hormone secretagogues protect cardiomyocytes from ischemia-reperfusion injury.\u003c\/em\u003e Endocrinology, 147(9), 4484–4492. \u003ca href=\"https:\/\/doi.org\/10.1210\/en.2006-0291\"\u003ehttps:\/\/doi.org\/10.1210\/en.2006-0291\u003c\/a\u003e\u003cbr\u003eDemonstrates that GHRP-6 and related GHS-R1a agonists exert direct cardioprotective effects in rat cardiomyocyte ischaemia-reperfusion models, independent of GH release, via anti-apoptotic and anti-inflammatory signalling — expanding the research scope of GHRP-6 beyond the GH axis.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248667287895,"sku":"G65","price":13.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/GHRP-65mg.png?v=1779536247"},{"product_id":"cjc-1295-no-dac-5mg","title":"CJC-1295 NO DAC 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/cjc-1295nodacg.png?v=1779534335\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eCJC-1295 NO DAC is a research peptide designed for scientific investigation into growth hormone secretion and metabolic processes. This 5mg vial contains lyophilized peptide powder suitable for laboratory use and study protocols. CJC-1295 without DAC (Drug Affinity Complex) offers a shorter half-life compared to its DAC counterpart, making it ideal for researchers exploring acute dosing schedules and rapid pharmacokinetic profiles. The peptide works by stimulating growth hormone-releasing hormone (GHRH) pathways, providing a focused tool for investigating GH dynamics in controlled research settings. Each vial is manufactured to pharmaceutical-grade standards and supplied as a stable, freeze-dried powder. Reconstitution with bacteriostatic water is recommended for storage and handling. Suitable for qualified researchers and institutions conducting peptide research.\u003c\/p\u003e\n\u003cp\u003ePeptide Sequence: GHRH analog (modified) Molecular Weight: 2094.24 g\/mol Purity: ≥98% (HPLC) Form: Lyophilized powder Vial Size: 5mg per vial Appearance: White to off-white lyophilized cake Storage: 2–8°C (refrigerated) or -20°C (long-term) Reconstitution: Bacteriostatic water (0.9% benzyl alcohol in saline) Half-life: 30 minutes (without DAC) Mechanism: GHRH receptor agonist Research Applications: GH secretion studies, metabolic research, pharmacokinetic investigations Stability: Stable when properly reconstituted and stored Intended Use: Research and laboratory use only Packaging: Sterile vial with flip-top cap\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C152H252N44O42\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution (Lyophilized Powder): Store in original vial at 2–8°C (refrigerated) for short-term use (up to 3 months). For long-term storage, keep at -20°C or below for up to 12 months. Protect from light and moisture. Keep vial sealed until ready for use. Avoid repeated freeze-thaw cycles. Storage After Reconstitution (Solution): Reconstituted solution should be stored at 2–8°C (refrigerated). Typical stability: 3–7 days when reconstituted with bacteriostatic water. Use sterile technique during reconstitution to maintain sterility. Store in sterile vials with appropriate sealing. Do not freeze reconstituted solution unless specifically required for your protocol. Discard any unused reconstituted solution after the recommended storage period.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRH Receptor Cloning and Agonist Binding\u003c\/strong\u003e\u003cbr\u003eMayo KE, et al. (1992). \u003cem\u003eMolecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone.\u003c\/em\u003e Molecular Endocrinology, 6(10), 1734–1744. \u003ca href=\"https:\/\/doi.org\/10.1210\/mend.6.10.1333056\"\u003ehttps:\/\/doi.org\/10.1210\/mend.6.10.1333056\u003c\/a\u003e\u003cbr\u003eReports the cloning and characterisation of the GHRH receptor (GHRHR), establishing the molecular target through which CJC-1295 (no DAC) exerts its GH-releasing effects and providing structural context for GHRH receptor agonist research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCJC-1295 Pharmacokinetics: DAC vs. No-DAC Comparison\u003c\/strong\u003e\u003cbr\u003eJetté L, et al. (2005). \u003cem\u003ehGRF1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: A Comparison of the Pharmacokinetics and Pharmacodynamics of Eight Bioconjugates.\u003c\/em\u003e Journal of Pharmacology and Experimental Therapeutics, 317(3), 1228–1237. \u003ca href=\"https:\/\/doi.org\/10.1124\/jpet.105.089755\"\u003ehttps:\/\/doi.org\/10.1124\/jpet.105.089755\u003c\/a\u003e\u003cbr\u003eDirectly compares GHRH analogues with and without albumin-binding modifications, providing the key pharmacokinetic reference for the shorter half-life (~30 minutes) and pulsatile GH release pattern characteristic of the no-DAC form.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePulsatile GH Release and Physiological Relevance\u003c\/strong\u003e\u003cbr\u003eGiustina A \u0026amp; Veldhuis JD. (1998). \u003cem\u003ePathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.\u003c\/em\u003e Endocrine Reviews, 19(6), 717–797. \u003ca href=\"https:\/\/doi.org\/10.1210\/edrv.19.6.0353\"\u003ehttps:\/\/doi.org\/10.1210\/edrv.19.6.0353\u003c\/a\u003e\u003cbr\u003eComprehensive review of the neuroendocrine regulation of pulsatile GH secretion, providing essential physiological context for research using short-acting GHRH analogues such as CJC-1295 (no DAC) to model endogenous GH pulse dynamics.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCJC-1295 Clinical Pharmacodynamics\u003c\/strong\u003e\u003cbr\u003eTeichman SL, et al. (2006). \u003cem\u003eProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.\u003c\/em\u003e Journal of Clinical Endocrinology \u0026amp; Metabolism, 91(3), 799–805. \u003ca href=\"https:\/\/doi.org\/10.1210\/jc.2005-1536\"\u003ehttps:\/\/doi.org\/10.1210\/jc.2005-1536\u003c\/a\u003e\u003cbr\u003eProvides critical comparative pharmacodynamic data; the sustained GH\/IGF-1 elevation observed with the DAC form contrasts directly with the acute, pulsatile profile of CJC-1295 (no DAC), making this an essential reference for researchers designing short-acting GHRH protocol studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRH Analogues in Metabolic Research\u003c\/strong\u003e\u003cbr\u003eFalutz J, et al. (2007). \u003cem\u003eMetabolic effects of a growth hormone-releasing factor in patients with HIV.\u003c\/em\u003e New England Journal of Medicine, 357(23), 2359–2370. \u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa072375\"\u003ehttps:\/\/doi.org\/10.1056\/NEJMoa072375\u003c\/a\u003e\u003cbr\u003eInvestigates the metabolic effects of a GHRH(1–29) analogue in a clinical research setting, demonstrating changes in body composition and lipid metabolism — providing relevant context for researchers studying the downstream metabolic consequences of GHRH receptor activation.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248700186967,"sku":"CND5","price":19.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/cjc-1295nodacg.png?v=1779534335"},{"product_id":"hexarelin-5mg","title":"Hexarelin 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/HEXARELIN_5MG_GLOSS.png?v=1779039263\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eHexarelin is a synthetic hexapeptide research compound studied for its potential to stimulate growth hormone secretion. Designed for laboratory and research applications, this 5mg formulation offers precise dosing for controlled experimental protocols. Each vial contains pharmaceutical-grade material suitable for in vitro and animal model studies. Hexarelin has been the subject of scientific investigation into growth hormone dynamics and metabolic pathways. Ideal for researchers and institutions requiring high-purity peptide compounds for advanced studies.\u003c\/p\u003e\n\u003cp\u003ePeptide Sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 Molecular Weight: 886.04 g\/mol Purity: ≥98% (HPLC) Physical Form: Lyophilized powder Vial Size: 5mg per vial Storage: Keep refrigerated at 2–8°C. Protect from light and moisture. Reconstitution: Dissolve in sterile water or bacteriostatic saline for injection. Research Applications: Growth hormone secretion studies, metabolic research, neuroendocrine investigations. Quality Assurance: Manufactured to pharmaceutical standards with certificate of analysis provided.\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C49H66N12O9 CAS Number: 140703-51-1 Empirical Composition: Carbon, hydrogen, nitrogen, and oxygen in hexapeptide structure with D-amino acid modifications. Structural Classification: Synthetic growth hormone-releasing peptide (GHRP) analogue.\u003c\/p\u003e\n\u003cp\u003eBefore Reconstitution (Lyophilized Powder): Store at 2–8°C in original sealed vial. Keep in a cool, dark place away from direct sunlight and moisture. Unopened vials remain stable for 24 months when stored properly. Avoid repeated temperature fluctuations. After Reconstitution (Solution): Once dissolved in sterile water or bacteriostatic saline, use immediately for optimal stability. If storage is necessary, keep reconstituted solution at 2–8°C for up to 7 days. For extended storage beyond one week, freeze at −20°C or below. Thaw at room temperature before use. Avoid multiple freeze-thaw cycles. Do not store at room temperature for extended periods.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eHexarelin: Discovery and GH-Releasing Activity\u003c\/strong\u003e\u003cbr\u003eDeghenghi R, et al. (1994). \u003cem\u003eGH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats.\u003c\/em\u003e Life Sciences, 54(18), 1321–1328. \u003ca href=\"https:\/\/doi.org\/10.1016\/0024-3205(94)90031-0\"\u003ehttps:\/\/doi.org\/10.1016\/0024-3205(94)90031-0\u003c\/a\u003e\u003cbr\u003eOriginal characterisation of hexarelin as a potent synthetic GHRP, demonstrating robust GH-releasing activity in both infant and adult rat models and establishing its pharmacological profile relative to GHRP-6.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHexarelin and GHS-R1a Receptor Binding\u003c\/strong\u003e\u003cbr\u003eMuccioli G, et al. (1998). \u003cem\u003eIdentification and characterization of a novel growth hormone-releasing peptide receptor in the rat brain and liver.\u003c\/em\u003e Neuroendocrinology, 67(4), 232–237. \u003ca href=\"https:\/\/doi.org\/10.1159\/000054319\"\u003ehttps:\/\/doi.org\/10.1159\/000054319\u003c\/a\u003e\u003cbr\u003eIdentifies and characterises the GHS-R1a receptor binding profile of hexarelin in rat brain and hepatic tissue, providing mechanistic insight into its central and peripheral GH-secretory actions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCardioprotective Effects of Hexarelin in Animal Models\u003c\/strong\u003e\u003cbr\u003eBisi G, et al. (1999). \u003cem\u003eHexarelin, a synthetic growth hormone-releasing peptide, improves cardiac function in rats with myocardial infarction.\u003c\/em\u003e European Journal of Pharmacology, 381(2–3), 135–141. \u003ca href=\"https:\/\/doi.org\/10.1016\/S0014-2999(99)00572-4\"\u003ehttps:\/\/doi.org\/10.1016\/S0014-2999(99)00572-4\u003c\/a\u003e\u003cbr\u003eDemonstrates hexarelin-mediated improvements in cardiac contractility and haemodynamic parameters in a rat myocardial infarction model, independent of GH release, suggesting direct cardiac receptor-mediated effects.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHexarelin and CD36 Receptor Interaction\u003c\/strong\u003e\u003cbr\u003eDemers A, et al. (2004). \u003cem\u003eHexarelin protects against atherosclerotic lesion development in apolipoprotein E-deficient mice.\u003c\/em\u003e Endocrinology, 145(2), 551–558. \u003ca href=\"https:\/\/doi.org\/10.1210\/en.2003-0686\"\u003ehttps:\/\/doi.org\/10.1210\/en.2003-0686\u003c\/a\u003e\u003cbr\u003eIdentifies CD36 as a non-GHS-R binding target for hexarelin and demonstrates attenuation of atherosclerotic lesion development in ApoE-deficient mice, expanding the mechanistic scope of hexarelin research beyond the GH axis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeuroendocrine and Metabolic Effects of Hexarelin\u003c\/strong\u003e\u003cbr\u003eArvat E, et al. (1997). \u003cem\u003eHexarelin, a synthetic GH-releasing peptide, stimulates GH, ACTH, cortisol and prolactin secretion in humans.\u003c\/em\u003e Journal of Clinical Endocrinology \u0026amp; Metabolism, 82(7), 2439–2444. \u003ca href=\"https:\/\/doi.org\/10.1210\/jcem.82.7.4055\"\u003ehttps:\/\/doi.org\/10.1210\/jcem.82.7.4055\u003c\/a\u003e\u003cbr\u003eCharacterises the neuroendocrine secretory profile of hexarelin in human subjects, documenting stimulation of GH alongside ACTH, cortisol, and prolactin — distinguishing its broader hypothalamic–pituitary axis activity from more selective GHRPs such as ipamorelin.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248702251351,"sku":"HX5","price":29.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/HEXARELIN_5MG_GLOSS.png?v=1779039264"},{"product_id":"cjc-1295-5mg-ipamorelin-5mg","title":"CJC-1295 5mg + Ipamorelin 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/cjc-1295-ipamorelin_6b4eee8e-78bb-492c-a784-b5d56c605f0a.png?v=1779391035\" alt=\"CJC-1295 + Ipamorelin\"\u003eCJC-1295 5mg + Ipamorelin 5mg is a synergistic peptide blend designed for research and laboratory use. This dual-peptide formulation combines a modified growth-hormone-releasing hormone analogue with a selective growth-hormone secretagogue, delivering complementary mechanisms of action for advanced GH-axis research. Each vial is manufactured to exacting standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions exploring peptide-based studies. Store in a cool, dry place away from direct light. For research purposes only.\u003c\/p\u003e\n\u003cp\u003eSpecifications: Active Ingredients: CJC-1295 (no DAC) and Ipamorelin Concentration: 5mg CJC-1295 + 5mg Ipamorelin per vial Purity: Research-grade Format: Lyophilized powder Storage: Cool, dry environment, 2–8°C (refrigerated) Shelf Life: Refer to batch documentation for expiration details Intended Use: Laboratory and research applications only Quality Standard: Manufactured to pharmaceutical-grade consistency protocols Suitable for qualified researchers, academic institutions, and licensed laboratories conducting peptide research and development studies.\u003c\/p\u003e\n\u003cp\u003eMolecular Formula CJC-1295: C₁₅₂H₂₅₂N₄₂O₄₂S Molecular Weight: 3,367.97 g\/mol Sequence Classification: 29-amino acid GHRH analogue with drug affinity complex modifications Purity Analysis: ≥98% by HPLC Molecular Formula Ipamorelin: C₃₈H₄₉N₉O₅ Molecular Weight: 711.87 g\/mol Sequence Classification: 5-amino acid selective GH secretagogue and ghrelin mimetic Purity Analysis: ≥98% by HPLC This molecular data supports advanced research into growth-hormone axis regulation, pulsatile GH release mechanisms, and receptor interaction studies.\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store the sealed vial at 2–8°C (refrigerated) or at room temperature (15–25°C) in a cool, dry place away from direct sunlight and heat sources. Keep in original packaging to protect from light exposure. Unopened vials maintain stability for the duration specified in batch documentation when stored under these conditions. Storage After Reconstitution: Once reconstituted with bacteriostatic water or appropriate diluent, store the solution at 2–8°C (refrigerated). Reconstituted solution should be used within the timeframe indicated in your batch documentation. Avoid repeated freeze-thaw cycles, which may compromise peptide integrity. Keep the vial upright and away from direct light during storage. General Handling: Maintain sterile technique during reconstitution. Do not expose to extreme temperatures or prolonged room temperature conditions after mixing. For research use only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eCJC-1295 Pharmacokinetics and Prolonged GH Release\u003c\/strong\u003e\u003cbr\u003eJetté L, et al. (2005). \u003cem\u003ehGRF1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: A Comparison of the Pharmacokinetics and Pharmacodynamics of Eight Bioconjugates.\u003c\/em\u003e Journal of Pharmacology and Experimental Therapeutics, 317(3), 1228–1237. \u003ca href=\"https:\/\/doi.org\/10.1124\/jpet.105.089755\"\u003ehttps:\/\/doi.org\/10.1124\/jpet.105.089755\u003c\/a\u003e\u003cbr\u003eCharacterises the extended half-life and sustained GH-releasing activity of CJC-1295 analogues via albumin-binding modifications, establishing the pharmacokinetic basis for prolonged GHRH receptor activation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCJC-1295 Clinical Dose–Response in Healthy Adults\u003c\/strong\u003e\u003cbr\u003eTeichman SL, et al. (2006). \u003cem\u003eProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.\u003c\/em\u003e Journal of Clinical Endocrinology \u0026amp; Metabolism, 91(3), 799–805. \u003ca href=\"https:\/\/doi.org\/10.1210\/jc.2005-1536\"\u003ehttps:\/\/doi.org\/10.1210\/jc.2005-1536\u003c\/a\u003e\u003cbr\u003eDemonstrates dose-dependent, sustained elevation of GH and IGF-1 following CJC-1295 administration, with a half-life of 5–8 days, supporting its use as a long-acting GHRH analogue in research models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin: Selectivity and GH Secretagogue Activity\u003c\/strong\u003e\u003cbr\u003eRaun K, et al. (1998). \u003cem\u003eIpamorelin, the first selective growth hormone secretagogue.\u003c\/em\u003e European Journal of Endocrinology, 139(5), 552–561. \u003ca href=\"https:\/\/doi.org\/10.1530\/eje.0.1390552\"\u003ehttps:\/\/doi.org\/10.1530\/eje.0.1390552\u003c\/a\u003e\u003cbr\u003eEstablishes ipamorelin as a highly selective GH secretagogue with minimal effect on cortisol, prolactin, or ACTH, distinguishing it from earlier GHRPs and making it a preferred tool for isolated GH-axis research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSynergistic GH Release: GHRH + GHS Combination\u003c\/strong\u003e\u003cbr\u003eBowers CY, et al. (1990). \u003cem\u003eOn the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.\u003c\/em\u003e Endocrinology, 114(5), 1537–1545. \u003ca href=\"https:\/\/doi.org\/10.1210\/endo-114-5-1537\"\u003ehttps:\/\/doi.org\/10.1210\/endo-114-5-1537\u003c\/a\u003e\u003cbr\u003eFoundational study demonstrating the synergistic amplification of GH release when GHRH analogues are combined with GH secretagogues, providing the mechanistic rationale for dual-peptide research protocols.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGhrelin Receptor Signalling and GHRP Mechanisms\u003c\/strong\u003e\u003cbr\u003eSmith RG, et al. (2007). \u003cem\u003ePeptidomimetic regulation of growth hormone secretion.\u003c\/em\u003e Endocrine Reviews, 28(3), 346–360. \u003ca href=\"https:\/\/doi.org\/10.1210\/er.2006-0048\"\u003ehttps:\/\/doi.org\/10.1210\/er.2006-0048\u003c\/a\u003e\u003cbr\u003eComprehensive review of GHS-R1a receptor signalling pathways activated by ipamorelin and related ghrelin mimetics, covering downstream effects on somatotroph function and GH pulse amplitude relevant to CJC-1295 + Ipamorelin combination studies.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53582550040919,"sku":"CP10","price":29.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/cjc-1295-ipamorelin_6b4eee8e-78bb-492c-a784-b5d56c605f0a.png?v=1779391035"}],"url":"https:\/\/www.mutantpeptides.com\/collections\/growth-hormone-peptides.oembed","provider":"Mutant Peptides Ltd","version":"1.0","type":"link"}